e-Zyvec today announces its acquisition by Polyplus with a focus on expanding process economics optimization efforts for cell and gene therapy developers and manufacturers.
Strasbourg, France, February 1, 2022 – Polyplus, a leading provider of upstream process solutions for advanced biologic and cell and gene therapy production from research to commercial grade, today announces the acquisition of e-Zyvec, a provider of DNA design and production services for tailor-made DNA vectors for gene-therapy, bio-manufacturing and research. Financial details were not disclosed.
“When we launched e-Zyvec 5 years ago, the idea was to bring a different type of genetic engineering service to the market leveraging today’s digital technology. Moving forward, we are excited to now join an established market leader like Polyplus where we will have the resources and capacity to continue developing and growing the e-Zyvec platform.,” said Sylvain Julien, President and Co-Founder at e-Zyvec.
“Thanks to our innovative conception and assembly of DNA molecules, we are able to propose tailor-designed vectors that provide options that add value to each customer process. Joining the Polyplus team is an organic transition for our team, enabling us to expand this technology across the global market. Our full team will carry forward in their current roles, delivering a layer of expertise and human capital that is invaluable in today’s market.” said Carine Morel, Managing Director and Co-Founder at e-Zyvec.
“Polyplus is evolving and growing, and this latest acquisition is an example of our strategy in action. We will continue to build out the existing portfolio, which is strong on its own, by adding complementary activities that make us a more effective and comprehensive partner to our customers, with a focus on expanding process economics optimization efforts for cell and gene therapy developers and manufacturers,” Mario Philips, CEO of Polyplus commented.
Polyplus is a leading provider of upstream process solutions for advanced biologic and cell and gene therapy production from research to commercial grade. Leveraging more than 20 years of innovative nucleic acid transfection expertise, upstream solutions are tailored to meet strict scientific and regulatory standards from research to clinical development phases. Headquartered in Europe, and with locations in the United States, and Asia Polyplus supplies an extensive, and growing, range of transfection reagents worldwide.
Learn more at www.polyplus-transfection.com.
e-Zyvec is a French biotech start-up specialized in genetic engineering, providing biopharmaceutical scientists and genetic researchers with sophisticated tailor-made DNA vectors. The integrated e-Zyvec platform supports consulting, design and assembly for personalized plasmid DNA vector production that is accurate, fast and cost-effective to generate new powerful molecular tools. Founded in 2016, e-Zyvec offers unique innovative technology for gene therapy, bioproduction and fundamental research.
Media Contact Information:
Alengo Nyamay’antu, PhD
Scientific Communication Specialist at Polyplus
Direct: +33 3 88 67 59 38